InSights Hub

Oncology


Showing 10 results in Oncology
Antineoplastic Extravasation and Geriatric Assessment Public Comment

ASCO Seeks Public Comments for Antineoplastic Extravasation and Geriatric Assessment Guidelines

Published on

The American Society of Clinical Oncology (ASCO) is seeking public feedback on two important guidelines: the Management of Antineoplastic Extravasation: ONS/ASCO Guideline, developed in collaboration with the Oncology Nursing Society (ONS), and the Geriatric Assessment: ASCO Global Guideline. These guidelines are designed to offer the most current recommendations based on the latest evidence available. The […]

Read More
Focus
Guidelines
Specialties
Oncology • Medical Oncology
SIO 2025 - Conference Preview

SIO 2025  – Conference Preview (Focus on Tumors)

Published on

The Society of Interventional Oncology’s Annual Scientific Meeting, SIO 2025, will be held in Las Vegas, Nevada. from January 30-February 3, 2025. This is their premier annual event that attracts more than 660 physicians, scientists, students, and other professionals in the cancer field with a focus on interventional oncology. If you have not yet registered […]

Read More
Focus
Conferences
Specialties
Oncology • Medical Oncology
Guidelines Side-By-Side Cervical Cancer Screening

Comparing Cervical Cancer Screening Guidelines – Guidelines Side-By-Side (Cervical Cancer Awareness Month)

Published on

January is Cervical Cancer Awareness Month, providing a valuable opportunity to increase awareness of cervical cancer and the importance of vaccination against human papillomavirus (HPV), the primary cause of cervical cancer. This year, the focus of Cervical Cancer Awareness Month is on emphasizing the significance of expanding access to HPV vaccines, regular screening, and cutting-edge […]

Read More
Focus
Guidelines
Specialties
Family Medicine • Infectious Disease • Internal Medicine - General • Obstetrics and Gynecology • Oncology • Public Health and General Preventive Medicine
Thoracic Oncologic Surgery - STS 2025 - Conference Preview

The 61st STS Annual Meeting – Conference Preview on Thoracic Oncologic Surgery

Published on

The 61st Society of Thoracic Surgeons (STS) Annual Meeting will be held from January 24 to 26, 2025 at the Los Angeles Convention Center in California. This prestigious event is the leading annual gathering in the field of cardiothoracic surgery, showcasing cutting-edge research, innovative techniques, and advancements in technology. Attendees will have the opportunity to […]

Read More
Focus
Conferences
Specialties
Oncology • Medical Oncology • Surgical Oncology • Thoracic Surgery
2025 ASCO GI Symposium - Conference Preview

2025 ASCO Gastrointestinal Cancers Symposium – Conference Preview

Published on

The 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium will be held from Thursday, January 23 to Saturday, January 25, 2025, at Moscone West in San Francisco, CA. This symposium serves as an important platform for staying abreast of the most recent advancements in research and gaining insights from leading experts on […]

Read More
Focus
Conferences
Specialties
Gastroenterology • Oncology • Medical Oncology
Guidelines+ Trials Spotlight - (Tecvayli) for Patients with Newly Diagnosed Multiple Myeloma

Tecvayli Clinical Trial Results for Patients With Newly Diagnosed Multiple Myeloma – Guidelines+ Trials Spotlight

Published on

On October 25, 2022, the US Food and Drug Administration (FDA) granted approval for Johnson & Johnson’s Tecvayli® (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma. This approval is specifically for patients who have previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug, and […]

Read More
Focus
Clinical Trials
Specialties
Oncology • Pulmonology

Irinotecan Liposome Injection (Onivide/Ipsen) – Guidelines+ Monographs

Published on

Our latest edition of the Guidelines+ Monographs Series will delve into the medication irinotecan liposome injection, marketed under the brand name Onivyde®  by Ipsen. Onivyde (irinotecan liposome injection) is a liposomal formulation of the topoisomerase I inhibitor irinotecan used in the treatment of pancreatic adenocarcinoma. Onivyde is indicated in combination with oxaliplatin, fluorouracil and leucovorin, […]

Read More
Focus
Medications
Specialties
Oncology
Guidelines+ Trials Spotlight - TROPION-Lung01 Phase III trial

EGFR-Mutated NSCLC (The TROPION-Lung01 Phase III Trial) – Guidelines+ Trials Spotlight

Published on

AstraZeneca and Daiichi Sankyo have collaboratively submitted a new Biologics License Application (BLA) for accelerated approval in the United States for datopotamab deruxtecan (Dato-DXd). This application aims to provide treatment for adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) non-small cell lung cancer (NSCLC) who have previously undergone systemic therapies, including […]

Read More
Focus
Clinical Trials
Specialties
Oncology • Pulmonology

USPSTF’s Cervical Cancer Screening Recommendation is Now Open for Public Comment

Published on

The United States Preventive Services Task Force (USPSTF) recently released their draft recommendation statement titled Cervical Cancer: Screening, which was published online on December 10, 2024. This recommendation serves as an update to the previous 2018 guideline. The latest draft remains consistent with the 2018 recommendation but includes a new recommendation. It now suggests that […]

Read More
Focus
Guidelines
Specialties
Internal Medicine - General • Obstetrics and Gynecology • Oncology • Preventive Medicine • Public Health and General Preventive Medicine
Guidelines+ Trials Spotlight - Metastatic Squamous Cell Carcinoma of the Head & Neck (STELLAR-305)

Metastatic Squamous Cell Carcinoma of the Head and Neck (STELLAR-305) – Guidelines+ Trials Spotlight

Published on

One year ago, Exelixis commenced their phase 2/3 pivotal trial to assess the efficacy of zanzalintinib in combination with pembrolizumab compared to pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Zanzalintinib, an oral drug developed by Exelixis, targets and inhibits receptor tyrosine kinases […]

Read More
Focus
Clinical Trials
Specialties
Oncology
« Back to InSights Hub